GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Quest PharmaTech Inc (TSXV:QPT) » Definitions » Cyclically Adjusted PB Ratio

Quest PharmaTech (TSXV:QPT) Cyclically Adjusted PB Ratio : 0.08 (As of Jun. 04, 2024)


View and export this data going back to 1999. Start your Free Trial

What is Quest PharmaTech Cyclically Adjusted PB Ratio?

As of today (2024-06-04), Quest PharmaTech's current share price is C$0.02. Quest PharmaTech's Cyclically Adjusted Book per Share for the quarter that ended in Oct. 2023 was C$0.24. Quest PharmaTech's Cyclically Adjusted PB Ratio for today is 0.08.

The historical rank and industry rank for Quest PharmaTech's Cyclically Adjusted PB Ratio or its related term are showing as below:

TSXV:QPT' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.08   Med: 1   Max: 2.5
Current: 0.08

During the past years, Quest PharmaTech's highest Cyclically Adjusted PB Ratio was 2.50. The lowest was 0.08. And the median was 1.00.

TSXV:QPT's Cyclically Adjusted PB Ratio is ranked better than
89.79% of 656 companies
in the Biotechnology industry
Industry Median: 1.745 vs TSXV:QPT: 0.08

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Quest PharmaTech's adjusted book value per share data for the three months ended in Oct. 2023 was C$0.391. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is C$0.24 for the trailing ten years ended in Oct. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Quest PharmaTech Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Quest PharmaTech's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quest PharmaTech Cyclically Adjusted PB Ratio Chart

Quest PharmaTech Annual Data
Trend Jan14 Jan15 Jan16 Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 4.88 0.66 0.35

Quest PharmaTech Quarterly Data
Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 0.35 0.34 0.33 0.27

Competitive Comparison of Quest PharmaTech's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Quest PharmaTech's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quest PharmaTech's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Quest PharmaTech's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Quest PharmaTech's Cyclically Adjusted PB Ratio falls into.



Quest PharmaTech Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Quest PharmaTech's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.02/0.24
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Quest PharmaTech's Cyclically Adjusted Book per Share for the quarter that ended in Oct. 2023 is calculated as:

For example, Quest PharmaTech's adjusted Book Value per Share data for the three months ended in Oct. 2023 was:

Adj_Book=Book Value per Share/CPI of Oct. 2023 (Change)*Current CPI (Oct. 2023)
=0.391/125.3095*125.3095
=0.391

Current CPI (Oct. 2023) = 125.3095.

Quest PharmaTech Quarterly Data

Book Value per Share CPI Adj_Book
201401 -0.024 97.261 -0.031
201404 -0.027 98.920 -0.034
201407 -0.031 99.315 -0.039
201410 -0.027 99.473 -0.034
201501 -0.034 98.209 -0.043
201504 -0.037 99.710 -0.046
201507 -0.032 100.579 -0.040
201510 -0.013 100.500 -0.016
201601 -0.015 100.184 -0.019
201604 -0.017 101.370 -0.021
201607 -0.024 101.844 -0.030
201610 -0.031 102.002 -0.038
201701 -0.030 102.318 -0.037
201704 -0.047 103.029 -0.057
201707 -0.024 103.029 -0.029
201710 -0.032 103.424 -0.039
201801 -0.044 104.056 -0.053
201804 -0.050 105.320 -0.059
201807 -0.054 106.110 -0.064
201810 -0.056 105.952 -0.066
201901 -0.061 105.557 -0.072
201904 -0.069 107.453 -0.080
201907 -0.073 108.243 -0.085
201910 -0.080 107.927 -0.093
202001 -0.091 108.085 -0.106
202004 0.627 107.216 0.733
202007 0.646 108.401 0.747
202010 0.669 108.638 0.772
202101 1.042 109.192 1.196
202104 1.038 110.851 1.173
202107 1.042 112.431 1.161
202110 0.989 113.695 1.090
202201 0.537 114.801 0.586
202204 0.530 118.357 0.561
202207 0.527 120.964 0.546
202210 0.521 121.517 0.537
202301 0.492 121.596 0.507
202304 0.462 123.571 0.468
202307 0.406 124.914 0.407
202310 0.391 125.310 0.391

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Quest PharmaTech  (TSXV:QPT) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Quest PharmaTech Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Quest PharmaTech's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Quest PharmaTech (TSXV:QPT) Business Description

Traded in Other Exchanges
N/A
Address
8123 Roper Road NW, Edmonton, AB, CAN, T6E 6S4
Quest PharmaTech Inc is a Canadian-based pharmaceutical company developing targeted cancer therapy with its lead product MAb AR9.6, under development for a novel target- truncated O-glycans on MUC16 discovered at the University of Nebraska Medical Center. The company is also developing products utilizing proprietary transdermal delivery technologies with a focus on dermatology and wound healing applications.
Executives
Ragupathy Madiyalakan Director

Quest PharmaTech (TSXV:QPT) Headlines

No Headlines